Race the hurdles of global clinical trials

Inceptua’s Edoardo Madussi shares his insights

The case in favour of running a global clinical trial is compelling: lower running costs, quicker timelines, and access to substantially larger patient populations all contribute to a more efficient drug development process. But running a multi-country trial is a complex undertaking. With an enormous number of variables at play, seemingly minor delays can create a knock-on effect which sends costs soaring and timelines completely out of whack. How can pharma companies reap the benefits of a global trial whilst ensuring patients are safe, and increasingly stringent waste and cost reduction targets are met?

Regional differences make planning for a multi-country study challenging and, without local staff on the ground, it’s hard for companies to get a clear picture of the requirements they need to meet and the possible pitfalls they may face. From the design stage, working with a partner who can advise on the challenges of designing an agile trial that takes account of local variations in availability of materials, regulatory requirements, and possible logistic challenges is critical.

“We have an extremely multi-national team with a huge range of languages spoken,” says Edoardo Madussi, Commercial Director of the Clinical Trial Services division at Inceptua, “and this is a massive support for the sponsors we work with. Often, sponsors can see the opportunities offered by conducting a trial in an emerging market but the challenges they face in trying to operate in that market seem too great. Partnering with Inceptua gives them the support of our locally based teams who can give them the insight they need to build a robust plan for their trial.”

Establishing what the opportunities and options are within a local market is the first challenge for clinical trial planners. The range of clinical supplies available locally, and what the regulations are around clinical trials, can vary significantly between markets and to have an understanding of this in the planning stage is important. Where sponsors do not have this knowledge in house, working with the correct partner can help reduce the time from study conception to implementation, thus avoiding snowballing costs.

Further on in the planning stage, finding a sourcing strategy to ensure that the necessary clinical supplies are available can be a particularly acute headache for clinical trial project teams. With the cost of drugs rising dramatically in recent years, clinical supplies have become one of the largest components in the total cost of a trial. Increasingly, many sponsors need an external partner to help them establish a sourcing strategy which is both robust and cost effective. Inceptua’s strategic procurement team have significant experience of working with sponsors in the early stages of trials to establish the best sourcing strategy for a specific trial. A number of factors may influence the decision, including local regulations, availability, and cost.

“Our team is able to advise on solutions which will give trials a better guarantee of continued supply, meaning the possible disruption to patients is minimal.” says Madussi. “We also ensure sourcing is done either directly through manufacturers or with trusted nominated distributors, giving clearer transparency of supply chains and minimising risk to patients.”

Considerable advancements in technology and changes in regulation mean the clinical trial landscape is always evolving, but the need for securely sourced and correctly handled clinical supplies is a fundamental aspect that clinical trial project teams cannot overlook. Having the input of an experienced sourcing partner who can guide project teams, and help them ensure they are finding solutions which will work in practice is critical to the successful delivery of a trial.

Once clinical trial teams have their plans in place, the patients have been recruited, and the trial sites made ready, it is critical to have support with warehousing and distribution to ensure the ready availability of clinical supplies to the trial sites.

In many emerging markets, finding appropriate warehousing facilities to store clinical supplies, and transport solutions to be able to ship them in a controlled manner to the correct trial site can be difficult. Without a footprint of their own to rely on, sponsors need a partner who can provide this support. Inceptua’s GDP standard warehousing and distribution partners give sponsors access to a secure network of facilities, along with the local regulatory knowledge to ensure clinical supplies are being handled in accordance with best practice, whilst ensuring local regulations are adhered to.

With over 20 years’ experience in moving clinical supplies across borders in all directions and across all continents, the in-house logistics team at Inceptua is able to help clinical trial teams forecast and plan for the needs of sites in any region, and can work closely with sponsors to ensure they understand the impact of customs requirements on both costs and timescales. Once the material is available at the local depot, Inceptua can coordinate with site teams to ensure the timely delivery of clinical supplies; an important step in ensuring patients in any given region can be assured of a high standard of treatment without interruption.

Global clinical trials are challenging for sponsors but with the opportunities for improved drug development they offer, they cannot be overlooked. Hosting trials in a range of markets will be an increasingly important part of the drug development process and sponsors will need to tackle the challenges head on to ensure they are able to reap the benefits on offer.

“Wherever we operate in the world, our focus is always on the patient. Helping sponsors deliver clinical trials which maximise the possible benefit to patients is central to all our work.” says Madussi. Partnering with Inceptua provides sponsors with the support they need to navigate a difficult landscape and ensure they are able to deliver trials on time and in budget, ultimately helping development treatments for patients in need.

Latest News and Insights

BIO

CEO and Board Member

Stefan Fraenkel

Stefan Fraenkel is the CEO of the Inceptua Group and is also on the Inceptua Board. He has extensive experience in the pharmaceutical industry. Before joining Inceptua, he held senior management positions at Sobi (Swedish Orphan Biovitrum), Sweden’s largest publicly listed specialty pharmaceutical company, leading Marketing & Sales and serving as Head of Corporate Development and Strategy.

Previously, Stefan worked at Pfizer and Wyeth in international commercial leadership roles across Europe and the USA, gaining deep insights into global pharmaceutical markets and strategies. Stefan has also spent part of his career in management consulting. Stefan holds a PhD in International Economics, an MBA, and a BSc in Engineering.

BIO

Member of the Board

Chris Hasslinger

Chris Hasslinger is a Partner of Vesey Street Capital Partners and serves as a member of the Firm’s Investment Committee. He joined VSCP in 2023 and is responsible for sourcing and evaluating new investment opportunities and general portfolio company management. Mr. Hasslinger has nearly three decades of experience in healthcare and technology strategy and deal-making within the industry as well as in investment banking and private equity. He has extensive M&A experience, having closed over $20 billion in transaction value, and has established and structured a number of large commercial partnerships.

BIO

Executive Vice Chairman

Alan Raffensperger

Alan Raffensperger has a robust leadership background in the pharmaceutical industry, having served as CEO of Inceptua and COO of Sobi (Swedish Orphan Biovitrum), along with significant international executive roles at Amgen, Roche, and Pharmacia.

He has also been CEO for venture capital-owned medical device companies, showcasing his versatility in healthcare leadership. Alan’s early career as an advanced life support paramedic provided a strong foundation in emergency healthcare.

He holds an MBA and a BA in Emergency Health Care Management.

BIO

Member of the Board

Blake Goodner

Blake Goodner is a founder member of the investment firm Bridger Capital. He previously worked as a healthcare analyst at Tiger Management and a healthcare investment banker at Morgan Stanley. He currently serves as an advisor and board member for a range of healthcare companies. Mr. Goodner has been a member of the Trinity College Board of Visitors and the Duke Annual Fund Executive Committee. He is a current advisory board member with The Duke Margolis-Center for Health Policy.

BIO

Member of the Board

Adam Feinstein

Adam Feinstein is the Managing Partner of Vesey Street Capital Partners. Mr. Feinstein has 30 years of investment experience exclusively in the healthcare services sector. Prior to founding Vesey Street Capital Partners in 2014, he was a Managing Director on Wall Street and a healthcare industry executive. He held the position of Senior Vice President of Corporate Development, Strategic Investments, and Office of the Chief Executive Officer at LabCorp. Before his tenure at LabCorp, he spent 14 years as the Managing Director in Equity Research at Lehman Brothers/Barclays Capital. Mr. Feinstein is the Chairman of VSCP’s investment committee. He is also actively involved in working with portfolio company executives and sourcing new investment opportunities. At the same time, he oversees all of the firm’s investment activities and employees.

BIO

Member of the Board

Larry Marsh

Larry is a General Partner of Vesey Street Capital Partners and serves as a member of the Firm’s Investment Committee. He joined VSCP in 2016, and currently sits on the Board of QualityMetric, Safecor Health, and HRGi. He is responsible for portfolio company management and for evaluating new investment opportunities. Prior to VSCP, Larry was EVP, New Market Development & Chief Strategy Officer at Fortune 10 AmerisourceBergen. Prior to that, Larry was the #1 ranked Healthcare Technology & Distribution analyst on Wall Street for over a decade, at Barclays, Lehman Brothers, Salomon Smith Barney, and Wheat First Butcher & Singer. Larry worked with Adam, Bryan, Dan, and Joe at Barclays and Lehman. Larry received a B.S. in Economics & Management as well as an M.B.A. from the University of Richmond, and an M.P.H. from Columbia University.

BIO

Member of the Board

Heyward Donigan

Heyward Donigan is a seasoned healthcare CEO, Board Member, and Private Equity Advisor with broad industry experience and a track record of profitable growth. From 2019 to 2023, Ms. Donigan served as Rite Aid’s president and chief executive officer, making her one of the few women CEOs of a Fortune 500 company. While at Rite Aid, Ms. Donigan led the company to through a major brand, merchandise and technology transformation, debt reduction/refinancing, while also leading the company through a pandemic. Ms.Donigan is currently a strategic advisor to Vesey Street Capital Partners, Arima Health, and a board member of OnMed.

BIO

Executive Chairman

Doug Cook

Doug Cook is the Executive Chairman at Inceptua. Mr. Cook began his career driving the early success of Livingston Healthcare, leading to the purchase by UPS to become what is today UPS’s Global Healthcare business. After Livingston Healthcare, Mr. Cook moved to AmerisourceBergen (now called Cencora/COR) in 1998 and had an impressive career overseeing most of Cencora’s high growth, manufacturer-facing business. Mr. Cook ultimately served as the Executive Vice President, President Commercialization and Animal Health for COR.

You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.

You are about to leave!

You are now leaving www.inceptuapharma.com to enter the Inceptua Group website: www.inceptua.com. Links to external websites are provided as a resource to the viewer, and the content is not controlled by Inceptua Pharma.

You are about to leave!

You are now leaving www.inceptuapharma.com to enter the Inceptua Group website: www.inceptua.com. Links to external websites are provided as a resource to the viewer, and the content is not controlled by Inceptua Pharma.

You are about to leave!

You are now leaving www.inceptuapharma.com to enter the Inceptua Group website: www.inceptua.com. Links to external websites are provided as a resource to the viewer, and the content is not controlled by Inceptua Pharma.

You are about to leave!

You are now leaving www.inceptuapharma.com to enter the Inceptua Group website: www.inceptua.com. Links to external websites are provided as a resource to the viewer, and the content is not controlled by Inceptua Pharma.

You are about to leave!

You are now leaving www.inceptuapharma.com to enter the Inceptua Group website: www.inceptua.com. Links to external websites are provided as a resource to the viewer, and the content is not controlled by Inceptua Pharma.

You are about to leave!

You are now leaving www.inceptuapharma.com to enter the Inceptua Group website: www.inceptua.com. Links to external websites are provided as a resource to the viewer, and the content is not controlled by Inceptua Pharma.

You are about to leave!

You are now leaving an Inceptua website. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Inceptua . Inceptua accepts no responsibility for the content or services of the linked site.